50% off Premium Yearly

NASDAQ:SBRA
This summary was created by AI, based on 1 opinions in the last 12 months.
Sabra Health Care REIT, identified with the symbol SBRA-Q, is highly recommended by experts as a top investment pick for 2026. It is currently trading at an attractive valuation of 12 times its funds from operations (FFO), which is significantly lower than the market average, making it a potentially lucrative opportunity for investors. Additionally, Sabra offers a 6.5% dividend yield, appealing to those seeking steady income. The company operates in the nursing and behavioral health sectors, which are poised to benefit from favorable demographic trends, and is expected to grow its earnings by 5.5% this year. Having experienced a 17% rise in value last year, Sabra demonstrates strong momentum, further supported by solid fundamentals, while also being well-positioned to adapt to technological advancements such as AI.
Sabra Health Care REIT is a American stock, trading under the symbol SBRA (previously SBRA-Q on Stockchase) on the NASDAQ (SBRA). It is usually referred to as NASDAQ:SBRA or SBRA
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on SBRA (previously SBRA-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Sabra Health Care REIT.
Sabra Health Care REIT was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Sabra Health Care REIT.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Sabra Health Care REIT.
Sabra Health Care REIT is followed by 6 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-12, Sabra Health Care REIT (SBRA) stock closed at a price of $18.73.
Her top pick of 2026. Trades at 12x FFO, half the market's, and pays a 6.5% dividend. They are in the nursing space (retirement and skilled), and behavioural health. Enjoys demographic winds. Earnings to grow 5.5% this year. Up 17% last year, so has momentum as well as fundamentals. Is not threatened by AI, and could even benefit Sabra.